# Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions

> **NCT00776217** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** loratadine 10 mg orally disintegrating tablets

## Key facts

- **NCT ID:** NCT00776217
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-07
- **Final completion:** 2006-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2008-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776217, "Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00776217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*